File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic factors in severe exacerbation of chronic hepatitis B

TitlePrognostic factors in severe exacerbation of chronic hepatitis B
Authors
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2003, v. 36 n. 8, p. 979-984 How to Cite?
AbstractForty-seven patients with severe hepatitis B exacerbation were compared with patients who had mild exacerbation (n = 96) or no exacerbation (n = 96). Seventeen patients (36.2%) died or underwent liver transplantation. Preexisting cirrhosis and a prothrombin time (PT) of >30 s were associated with adverse outcome in 60.9% and 87.5% of patients, respectively. The rate of adverse outcome increased to 92.3% when albumin levels of ≤35 g/L and bilirubin levels of >200 μM were present. Other factors associated with adverse outcomes included peak bilirubin level, peak PT, time to reach peak PT, and the presence of encephalopathy and/or ascites. There was no difference in the frequency of precore mutations in patients with severe or mild exacerbation or without exacerbation. A significantly lower prevalence of core promoter mutants was found in patients with severe exacerbation (50%), compared with those who had mild exacerbation (81.3%; P = .004). Patients with severe exacerbation of hepatitis B with poor prognostic factors should be considered for early liver transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/42151
ISSN
2021 Impact Factor: 20.999
2020 SCImago Journal Rankings: 3.440
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorSablon, Een_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLi, TMen_HK
dc.contributor.authorYuan, HJen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorDoutreloigne, Jen_HK
dc.contributor.authorBogaerts, Ven_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2007-01-08T02:30:20Z-
dc.date.available2007-01-08T02:30:20Z-
dc.date.issued2003en_HK
dc.identifier.citationClinical Infectious Diseases, 2003, v. 36 n. 8, p. 979-984en_HK
dc.identifier.issn1058-4838en_HK
dc.identifier.urihttp://hdl.handle.net/10722/42151-
dc.description.abstractForty-seven patients with severe hepatitis B exacerbation were compared with patients who had mild exacerbation (n = 96) or no exacerbation (n = 96). Seventeen patients (36.2%) died or underwent liver transplantation. Preexisting cirrhosis and a prothrombin time (PT) of >30 s were associated with adverse outcome in 60.9% and 87.5% of patients, respectively. The rate of adverse outcome increased to 92.3% when albumin levels of ≤35 g/L and bilirubin levels of >200 μM were present. Other factors associated with adverse outcomes included peak bilirubin level, peak PT, time to reach peak PT, and the presence of encephalopathy and/or ascites. There was no difference in the frequency of precore mutations in patients with severe or mild exacerbation or without exacerbation. A significantly lower prevalence of core promoter mutants was found in patients with severe exacerbation (50%), compared with those who had mild exacerbation (81.3%; P = .004). Patients with severe exacerbation of hepatitis B with poor prognostic factors should be considered for early liver transplantation.en_HK
dc.format.extent102246 bytes-
dc.format.extent3035 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/en_HK
dc.relation.ispartofClinical Infectious Diseasesen_HK
dc.rightsClinical Infectious Diseases. Copyright © University of Chicago Press.en_HK
dc.subject.meshHepatitis b virus - drug effects - geneticsen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMultivariate analysisen_HK
dc.subject.meshPromoter regions (genetics)en_HK
dc.subject.meshSerologic testsen_HK
dc.titlePrognostic factors in severe exacerbation of chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1058-4838&volume=36&issue=8&spage=979&epage=984&date=2003&atitle=Prognostic+factors+in+severe+exacerbation+of+chronic+hepatitis+Ben_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1086/374226en_HK
dc.identifier.pmid12684909-
dc.identifier.scopuseid_2-s2.0-0037447201en_HK
dc.identifier.hkuros77828-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037447201&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue8en_HK
dc.identifier.spage979en_HK
dc.identifier.epage984en_HK
dc.identifier.isiWOS:000182124700007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridSablon, E=6603694538en_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridLi, TM=7406375213en_HK
dc.identifier.scopusauthoridYuan, HJ=7402446707en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridDoutreloigne, J=6603727456en_HK
dc.identifier.scopusauthoridBogaerts, V=12787322000en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.issnl1058-4838-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats